CRSWNP and dupilumab – real-world data after more than 2 years of clinical use
Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S323-S324
DOI: 10.1055/s-0044-1785097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Kenan Dennis Sakmen und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Dupilumab has been approved as add-on therapy for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) since 2019. The aim of this study is to investigate compliance, associated comorbidities, symptom development and side effects after several years of clinical use. Material and methods A total of 72 patients were included in the retrospective study between 07/2020 and 08/2023. Endpoints were changes in the SNOT-22 questionnaire, the nasal polyp score (NPS), the olfactory test (GT) using Sniffin Sticks, and the blood eosinophil concentration. The observation period extended from T0 (baseline) to 3, 6, 12 and 24 months after the start of therapy (T1-4). Comorbidities were also recorded.
Results
45.9% of the patients had comorbid asthma, 30.6% had NSAID hypersensitivity , 7 patients were lost to follow-up, 2 patients continued therapy with a practicing colleague, 6 patients switched therapy and 4 patients discontinued therapy. Initially, the SNOT-22 showed a mean score of 58.1/110 (n=71), the NPS was 5.1/8 (n=72), the GT was 3.9/12 (n=17), the blood eosinophil concentration was 0.44/nl. The three, six, 12 and 24 month course showed a highly significant improvement in SNOT-22, NPS and GT. Blood eosinophil levels did not change significantly.
Conclusion
In patients with CRSwNP, dupilumab leads to a reduction in existing polyps and a significant reduction in sinonasal symptoms in the long term, accompanied by an improvement in olfactory performance. Anamnestic evidence shows good applicability with a low side effect profile. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Sakmen, K. D., Leinung, M., Stöver, T., & Loth, A. (2024). CRSWNP and dupilumab – real-world data after more than 2 years of clinical use. Laryngo-Rhino-Otologie, 103(S 02 S 02), S323-S324. https://doi.org/10.1055/s-0044-1785097
Vancouver
Sakmen KD, Leinung M, Stöver T, Loth A. CRSWNP and dupilumab – real-world data after more than 2 years of clinical use. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S323-S324. doi:10.1055/s-0044-1785097
BibTeX
@article{Sakmen2024,
author = {Sakmen, Kenan Dennis and Leinung, Martin and Stöver, Timo and Loth, Andreas},
title = {CRSWNP and dupilumab – real-world data after more than 2 years of clinical use},
journal = {Laryngo-Rhino-Otologie},
year = {2024},
volume = {103},
number = {S 02 S 02},
pages = {S323--S324},
doi = {10.1055/s-0044-1785097}
}
EUVIMED